Selective drug targeting to a tumour is required for the effective treatment of solid tumours. If this objective could be achieved, undesirable toxicities of a drug to normal tissues, such as the bone marrow, will be reduced and therapeutic efficacy will improve. We have developed an effective way of achieving highly tumouritropic delivery of drugs by using macromolecules and taking advantage of the unique characteristics of the blood and lymphatic vasculatures of tumour tissue (Maeda et al., 1979a,b; Takeshita et al., 1982; Maeda et al., 1984; Matsumura & Maeda, 1986; Maeda & Matsumura, 1989; Maeda, 1991; Maeda et al., 1992) . Namely, most solid tumours possess vasculature that is densely and irregularly developed, and hyperpermeable to macromolecules; however, they usually lack functioning lymphatics, which leads to selective deposition of macromolecules in tumour tissues. We have adopted a term, enhanced permeability and retention (EPR) effect, to describe this phenomenon Matsumura & Maeda, 1986; Maeda & Matsumura, 1989; Maeda, 1991; Maeda et al., 1992) .
Antiontensin II (AT-II)-induced hypertension has been proved to result in selective increase in the blood flow in tumour tissue only and not in normal tissue Hori et al., 1991) . Improved antitumour activity was reported in the clinical setting by use of this AT-II method (Wakui & Sato, 1984) . The rationale behind this method is based on a hypothesis that increased blood flow will cause a parallel increase in the distribution of the drugs Wakui & Sato, 1984) , because small molecular drugs would diffuse freely in and out of the blood vessels. Under these circumstances the AT-II method was explored only for mostly conventional small molecular drugs (e.g. doxorubicin, mitomycin C, etc.). However, it Maeda, 1986; Iwai et al., 1987; Maeda & Matsumura, 1989; Maeda, 1991; Maeda et al., 1992) . Thus, it would be useful to study the influence of AT-IT-induced hypertension on the distribution of macromolecules in tumour and normal tissues. SMANCS, styrene-maleic acid copolymer-conjugated neocarzinostatin (Maeda et al., 1979a,b; Takeshita et al., 1982; Maeda et al., 1984; Maeda et al., 1985) (Khaw et al., 1980; Hnatowich et al., 1982; Matsumura & Maeda, 1986 Evaluation of toxicities SMANCS at a dose giving 50% lethality (LD50) (2 mg kg-') was injected i.v. via the tail vein of normal rats without tumour under hypertensive or normotensive conditions. The AT-II infusion was continued for 15 min as described. After 24 h, body weight was measured and blood was collected for determination of platelet and white blood cell (WBC) counts. The frequency and severity of diarrhoea were also recorded.
Results

Distribution of [3H]methylglucose
Distribution of the radioactivity in the tumour and the bone marrow was quantified at 15, 20, or 60 min after i.v. administration of [3H]methylglucose under hypertensive or normotensive conditions. As shown in Table I We also tested the effect of AT-II-induced hypertension on the distribution of the macromolecular anticancer agents, SMANCS (16,000Da) (Maeda et al., 1979a; Maeda et al., 1985) , which is known to bind to albumin in the blood stream and hence behaves similar to albumin (Kobayashi et al., 1988) . Table III shows the concentration of SMANCS in the tumour, the bone marrow, and the small intestine at 1 and 6 h after injection, as determined by ELISA. The distribution of SMANCS to tumour was augmented significantly over time even under normotensive conditions, but it was enhanced even further under AT-II-induced hypertension. In contrast, distribution to bone marrow or small intestine tended to be reduced at 1 h after injection. Furthermore, enhanced intratumour concentration of the drug by using artificial hypertension was retained for 6 h, which is consistent with the results for [5'Cr]BSA. However, EPR effect alone facilitated much more (about 7-fold) accumulation of these macromolecules in tumour tissue over the bone marrow, or tumour over the intestine about 2-fold, where induced hypertension augmented EPR effect only about 2-fold.
The distribution ratios (tumour vs the normal tissues) of these macromolecules were calculated: namely, their concentration in tumour was divided by that in the bone marrow or the small intestine for each animal. As shown in Figure 1 , selective accumulation of [51Cr]BSA in the tumour was improved about 1.5-2-fold under AT-II-induced hypertension at both 1 and 6 h. Tumour-specific accumulation of SMANCS was also augmented by about 30-160% under artificial hypertension (Figure 2 ). As reported by Suzuki et al. (1981) and Hori et al. (1991) , AT-II-induced hypertension produces a selective increase in blood flow volume in tumour tissue because of the absence of autoregulation of tumour blood flow. In great contrast, normal tissue has an autoregulatory flow volume regardless of the blood pressure applied. An increase in blood flow is expected to result in increased drug delivery to tumour. On the basis of this principle, AT-IL-induced hypertensive chemotherapy has been initiated in Japan (Tables II and III) . In general, macromolecules and lipids in the interstitial space are known to be recovered mainly by the lymphatics in normal tissues (Courtice, 1963), but they seemed unlikely to be cleared from tumour tissue effectively Iwai et al., 1987; Maeda et al., 1984; Matsumura & Maeda, 1986) . If the accumulated macromolecules in tumour could be drained by the operating lymphatics there would be no accumulation of the macromolecular drugs as in normal tissue. The results showed, however, that this appears to be unlikely because of the high accumulation in tumour (Tables II and III (Figures 1 and 2 ) as previously observed Matsumura & Maeda, 1986 ) and attributed to the EPR effect.
The results became more pronounced when the blood pressure was increased while drugs were administered (Tables II  and III) . Unlike small molecules, macromolecules and lipids themselves are tumouritropic because of the EPR effect, as reported previously Matsumura & Maeda, 1986; Maeda & Matsumura, 1989; Maeda, 1991; Maeda et al., 1992) . Using another macromolecule (hydroxypropylmethacrylamide copolymer) developed by a joint effort of groups in the UK and Czechoslovakia, we also observed a time-dependent increase in intratumour concentration (EPR effect) (Seymour, L., Miyamoto, Y., et al., unpublished).
We have also found another phenomenon that little lymphatic clearance of lipids (Konno et al., 1984a,b; Iwai et al., 1984; Maeda et al., 1984; Iwai et al., 1987) and macromolecules Matsumura & Maeda, 1986; Maeda & Matsumura, 1989; Maeda, 1991) from solid tumours takes place.
The EPR effect can be attributed to a hypervascularised state resulting from tumour angiogenesis (Folkman & Klagsbrun, 1987) , and incomplete vascular architecture and leakiness (Suzuki et al., 1987; Skinner et al., 1990) . Furthermore, we found a mechanism that allows a high local concentration of bradykinin which enhances vascular permeability; in which tumour cells activate the Hageman factor/ kallikrein/kinin cascade Matsumura et al., 1990; Matsumura et al., 1991) . As a consequence, vascular permeability will be elevated. Another permeability-enhancing factor that would function in an additive manner to the kinin system is also known (Senger et al., 1983; Dvorak et al., 1985) .
It is suggested that the major obstacle to the delivery of macromolecules to solid tumours is the elevated interstitial fluid pressure in tumour tissues (Jain, 1990) . Our work described here indicates that AT-II-induced hypertension is an effective way for overcoming such an obstacle of intratumoural fluid pressure by increasing blood pressure/flow/ vascular surface area in tumour tissue Hori et al., 1983; Hori et al., 1984) , which may all enhance the convective influx of macromolecules into the tumour compartment out of the blood capillary. Present and previous observations of EPR effect or higher retention in tumour indicate reverse transfer of macromolecules and lipids does not seem to occur as a vascular barrier or characteristics.
The results described here also imply that this method may improve the delivery of monoclonal antibodies to tumour tissue. Several approaches have been examined to increase the tumour uptake of monoclonal antibodies so far (e.g. Smyth et al., 1987; Kalofonos et al., 1990; Cope et al., 1990; Russel et al., 1990 ). Recently we reported that ATI-ITinduced hypertension combined with the use of kininase inhibitor enhanced the tumour localisation of a monoclonal antibody up to 200% of control (Noguchi et al., 1992) . Kininase inhibitor might enhance the vascular permeability by prolonging the action of kinin Matsumura et al., 1988; Matsumura et al., 1990; Matsumura et al., 1991) .
The second advantage clarified in this study was the reduction in accumulation of the drug by normal tissues, such as the bone marrow and the small intestine, by using macromolecular drugs rather than small molecules in induced hypertension chemotherapy. AT-II-induced hypertension decreased the blood flow volume in the kidneys because of vascular constriction, resulting in reduced renal toxicity of cisplatin (Kuroiwa et al., 1987) . In general, however, arterial blood flow remains constant in normal tissues, in the range between 50 and 150 mmHg, by autoregulatory contraction of arterioles as described above , with some exceptions such as the kidney (Kuroiwa et al., 1987) . It is consistent then that accumulation of [3H]methylglucose in bone marrow was little affected by manipulating blood pressure, as shown in Table I . In contrast to the accumulation of [3H] methylglucose, the accumulation of macromolecules represented by [5'Cr] BSA and SMANCS in the bone marrow was reduced under hypertensive conditions as shown in Tables II and III. A decrease in the distribution of macromolecules to normal tissues under AT-TI-induced hypertension was confirmed by the reduction of the toxicity of SMANCS administered at a lethal dose (Table IV) . Significant protection against leukopenia, diarrhoea, and loss of body weight was noted, reflecting the reduced delivery of SMANCS to these organs (Table III) . Accordingly, AT-TIinduced hypertension can improve the therapeutic index of macromolecular anticancer agents.
